Skip to content
lifestyle.careersavvy.co.uk
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
SynAct Pharma
SynAct Pharma Draws Down the Second Tranche of The Financing Facility with Fenja Capital II A/S And Resolves on A Directed Issue of Convertibles to Fenja
November 18, 2026
SynAct Pharma CEO has Acquired Shares in the Company
November 16, 2026
Sten Sörensen resign from Board of Directors of SynAct Pharma
November 16, 2026
SynAct Pharma Announces Notice of Allowance of a US Patent Covering the Resomelagon Tablet
November 13, 2026
SynAct Pharma Announces Attendance and Presentation at Upcoming Investor Conferences
November 4, 2026
SynAct Pharma Announces Initiation of Coverage by BioVal BioStock Analytics
November 3, 2026
SynAct Pharma Publishes Q3 2026 Interim Results
November 3, 2026
SynAct Pharma Signs First Commercial Partnership for Resomelagon with Leading Brazilian Pharmaceutical Company
October 27, 2026
SynAct Pharma to Participate in Investor and Partnering Conferences
September 22, 2026
WHO Identifies Resomelagon as One Of Six Dengue Drug Candidates with Evidence Supporting Further Clinical Development
September 16, 2026
1
2
Next Page
→